Bueno Muiño, CoraliaMartín, MiguelMonte Millán, María delGarcía Saénz, José ÁngelLópez Tarruella, Sara2023-06-222023-06-222022-01-202072-669410.3390/cancers14030512https://hdl.handle.net/20.500.14352/71619Classical clinical research has been developed according to immunohistochemical breast cancer subtypes, instead of designing trials specifically for each molecular subtype. Efforts in de-escalating treatment should focus on identifying a subgroup of HER2 oncogene addicted tumours that are especially sensitive to anti-HER2 therapies and, thus, spare unnecessary treatments. A prognostic assay that integrates molecular tumour features with clinical and pathologic variables and accurately defines a group of HER2 addicted tumours remains the best candidate among these strategies.engAtribución 3.0 Españajournal articlehttps://doi.org/10.3390/cancers14030512https://www.mdpi.com/2072-6694/14/3/512/htmopen accessearlyHER2+escalationde-escalationintrinsic subtypeHER2-enrichedOncología3201.01 Oncología